Parkinson's Disease Mechanisms and TreatmentsGut microbiota and health
TL;DR
Although recent studies suggest the dysbiosis of gut microbiome in multiple system atrophy, as a contributor to dysfunctional intestinal barrier, new methods, including fecal RT-QuIC, smell testing, microbiota replacement, and gene-editing therapies, offer more promising evidence for diagnosis and disease-modifying therapies.
Abstract
Although recent studies suggest the dysbiosis of gut microbiome in multiple system atrophy (MSA), particularly a decrease in Akkermansia muciniphila, as a contributor to dysfunctional intestinal barrier and alpha-synuclein spreading to the brain, new methods, including fecal RT-QuIC, smell testing, microbiota replacement, and gene-editing therapies, offer more promising and early experimental evidence for diagnosis and disease-modifying therapies.
Depletion of SCFA-producing gut bacteria is a consistent feature of Alzheimer’s disease across diverse populations and restoring SCFA-mediated gut-brain communication represents a promising disease-modifying strategy for early AD intervention.
Zong-Xin Ling, Sheng-Yu Huang, Yi-Wen Cheng et al.· Current Research in Microbia...· 1 citation
Parkinson's disease (PD) is a progressive neurodegenerative disease that is associated with the loss of dopaminergic neurons and the formation of α-synuclein aggregates in the brain. Changes in the gut microbiota have been closely associated with PD pathophysiology and may contribute to disease-related processes throug...
Madhavi Porwal, R. Malviya, Phool Chandra et al.· Journal of Neuroimmunology· 0 citations
The findings support a biologically plausible role for gut-related mechanisms in disease pathophysiology, with a preliminary signal for more pronounced involvement in gut-first PD phenotypes that remains to be confirmed.
Pulkit Mehrotra, K. Vengadakrishnan, Puneet Mehrotra et al.· Frontiers in Medicine· 0 citations
Introduction Parkinson's disease (PD) is increasingly recognized as a multisystem disorder in which gastrointestinal dysfunction and gut microbial alterations may contribute to disease pathophysiology. Although most microbiome research in PD has focused on bacteria, growing evidence suggests that the gut ecosystem shou...
Hui-Ye Han, Owen D. Luo, Kevin Li et al.· Frontiers in Cellular and In...· 0 citations
Introduction Atypical parkinsonian syndromes (APS) such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal syndrome (CBS) pose a major clinical challenge due to their progressive disease course, reduced life expectancy and resistance to dopaminergic therapy. The gut microbiome has g...
Samiullah Amin Khan, T. Hegelmaier, Florian Wegner et al.· Journal of Parkinson's Disea...· 0 citations
Rather than presenting the microbiome as a single cause of ASD, this framework may support future precision approaches using microbiome monitoring, metabolite profiling, biological subgrouping, strain-specific probiotics, and targeted dietary or microbial interventions.
Eva Sclabassi, J. Hur, Ji-Ying Ling et al.· Frontiers in child and adole...· 0 citations
Zero-knowledge proofs can verify computing results without rerunning workloads or exposing sensitive data. Magnetar helps bring them into the mainstream with support for standard programming languages, major speed gains, and quantum-resistant security. The post Proof-based general-purpose computing with Magnetar appeared first on Microsoft Research.
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
